Want to see IN:VINEETLAB full AI Analyst Report?
Top Page
Vineet Laboratories Ltd.
(VINEETLAB)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹34.00
▼(-16.07% Downside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by weak and inconsistent cash generation and a volatile multi-year revenue/profit history, despite a notable earnings recovery and improved leverage in 2026. Technical indicators are moderately supportive (price above major moving averages with positive MACD), but the high P/E and lack of dividend support limit the valuation contribution.
Positive Factors
Earnings Recovery
The move from a deep 2025 loss to positive net margin, alongside stronger operating margins, shows a meaningful earnings recovery. This improves internal funding potential and demonstrates that the business can restore profitability, although the still-thin margin means durability remains to be proven.
Negative Factors
Weak Cash Generation
Large negative operating and free cash flow in 2026 indicate that reported earnings are not converting reliably into liquidity. Persistent cash deficits can increase reliance on financing, constrain investment capacity, and leave the company more exposed when demand or profitability weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Earnings Recovery
The move from a deep 2025 loss to positive net margin, alongside stronger operating margins, shows a meaningful earnings recovery. This improves internal funding potential and demonstrates that the business can restore profitability, although the still-thin margin means durability remains to be proven.
Read all positive factors
Vineet Laboratories Ltd. (VINEETLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹699.49M
Dividend Yield1.64%
Average Volume (3M)45.40K
Price to Earnings (P/E)42.6
Beta (1Y)0.59
Revenue Growth-20.79%
EPS GrowthN/A
CountryIN
Employees57
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.85
Shares Outstanding19,206,266
10 Day Avg. Volume94,760
30 Day Avg. Volume45,398
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.71
Price to Sales (P/S)0.54
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vineet Laboratories Ltd. Business Overview & Revenue Model
Company Description
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efa...
Vineet Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
47
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 594.01M | 749.95M | 1.51B | 2.12B | 1.91B |
| Gross Profit | 142.82M | -124.68M | 139.85M | 399.65M | 454.26M |
| EBITDA | 84.79M | -142.96M | 67.32M | 77.83M | 134.47M |
| Net Income | 11.11M | -201.91M | 10.27M | 12.53M | 66.39M |
Balance Sheet | |||||
| Total Assets | 1.25B | 945.40M | 1.17B | 1.16B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 170.75M | 6.69M | 2.28M | 6.31M | 181.17M |
| Total Debt | 453.25M | 400.47M | 443.00M | 310.89M | 307.04M |
| Total Liabilities | 791.81M | 798.92M | 821.48M | 821.66M | 1.00B |
| Stockholders Equity | 456.02M | 146.48M | 347.24M | 336.83M | 332.18M |
Cash Flow | |||||
| Free Cash Flow | -180.10M | 104.46M | -116.61M | -172.50M | 77.15M |
| Operating Cash Flow | -168.13M | 114.91M | -114.27M | -96.16M | 77.15M |
| Investing Cash Flow | -12.14M | -31.82M | -22.22M | -66.86M | -35.72M |
| Financing Cash Flow | 346.29M | -82.30M | 84.30M | 2.73M | 119.55M |
Vineet Laboratories Ltd. Technical Analysis
Positive
40.51
Price Trends
37.51
Negative
36.03
Positive
34.79
Positive
Market Momentum
-0.41
Negative
49.82
Neutral
67.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VINEETLAB, the sentiment is Positive. The current price of 40.51 is above the 20-day moving average (MA) of 36.24, above the 50-day MA of 37.51, and above the 200-day MA of 34.79, indicating a neutral trend. The MACD of -0.41 indicates Negative momentum. The RSI at 49.82 is Neutral, neither overbought nor oversold. The STOCH value of 67.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VINEETLAB.
Vineet Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹6.19B | 39.48 | ― | ― | -2.70% | -15.41% | |
61 Neutral | ₹9.90B | 12.30 | ― | 0.37% | 13.23% | 22.22% | |
59 Neutral | ₹7.74B | 19.09 | ― | 0.80% | 49.58% | 43.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ₹699.49M | 42.59 | ― | 1.64% | -20.79% | ― | |
44 Neutral | ₹2.36B | -22.99 | ― | 0.43% | -39.30% | -700.73% | |
43 Neutral | ₹1.27B | -15.37 | ― | 5.35% | 16.37% | -1367.53% |
* General Sector Average
IN:VINEETLAB
Vineet Laboratories Ltd.
36.42
1.01
2.85%
IN:DIAMINESQ
Diamines & Chemicals Ltd.
235.00
-68.15
-22.48%
IN:DMCC
DMCC Speciality Chemicals Limited
310.15
6.52
2.15%
IN:INDOAMIN
Indo Amines Limited
136.35
-2.19
-1.58%
IN:PRIMO
Primo Chemicals Limited
25.53
1.16
4.76%
IN:ISHANCH
Ishan Dyes and Chemicals Limited
46.54
-22.78
-32.86%
Vineet Laboratories Ltd. Corporate Events
Vineet Laboratories Claims SEBI Corporate Governance Exemption for June Quarter
Jul 30, 2026
Vineet Laboratories Ltd. has formally notified the BSE and NSE that corporate governance compliance requirements under Regulation 27(2) of SEBI’s Listing Obligations and Disclosure Requirements are not applicable for the quarter ended June 3...
Vineet Laboratories Strengthens Board With Appointment of Executive Director Rajesh Kumar Kathulla
Jul 21, 2026
Vineet Laboratories Ltd. has announced a change in its board composition with the appointment of Hyderabad-based entrepreneur Rajesh Kumar Kathulla as an Additional Executive Director, effective 11 June 2026. His five-year term is subject to share...
Vineet Laboratories Redesignates Promoter Ramana as Non-Executive Director
Jul 21, 2026
Vineet Laboratories Ltd. has announced that Managing Director Mr. Gaddam Venkata Ramana will cease to hold the MD position effective July 21, 2026. He remains on the board as a director and is being redesignated as a non-executive director, while ...
Vineet Laboratories Sets Board Meet to Approve FY26 Results, Keeps Trading Window Shut
Jul 11, 2026
Vineet Laboratories Ltd. has scheduled a board meeting on July 15, 2026, to consider and approve its audited standalone financial results for the fourth quarter and the financial year ended March 31, 2026. This step underscores the company’s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.